United Health Products provides regulatory update

Henderson, NV, May 18, 2022 (GLOBE NEWSWIRE) — via NewMediaWire — United Health Products, Inc. (OTCPK: UEEC), (UHP) today provided an update on its FDA regulatory process.

Regulatory Review
As previously reported, on April 20, 2022, UHP submitted to the United States Food & Drug Administration (FDA) a completed, electronically formatted Premarket Approval (PMA) response for its HemoStyp™ hemostatic gauze and, as usual, asked for a meeting with the commission in charge of studying his PMA request. UHP has accepted FDA’s offer to meet on July 6, 2022 and expects to receive comments on its final response prior to that meeting. The company will continue to engage with members of the review committee to address any remaining inquiries and ensure a productive interaction in July. There is no guarantee that the PMA request will be approved.

Investor Relations:
Philippe Niemetz
212 344-6464
p.niemetz@panconsultants.com

About United Health Products — United Health Products develops, manufactures and markets HemoStyp™, a patented hemostatic agent based on neutralized oxidized regenerated cellulose (NORC). HemoStyp is an all natural product designed to control bleeding. UHP currently offers a range of hemostatic products to the dental, veterinary and consumer markets, and is focused on gaining clearance to enter the human surgery market.

For more information on UHP, visit: www.unitedhealthproductsinc.com or contact the company at info@unitedhealthproductsinc.com

Safe Harbor Statement Under the Private Securities Litigation Reform Act of 1995: This press release may contain forward-looking information within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements that include the words “believes”, “expects”, “anticipates” or similar expressions. These forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the Company’s actual results, performance or achievements to differ materially from those expressed or implied by such forward-looking statements.


Source link

Comments are closed.